View ValuationCorline Biomedical 将来の成長Future 基準チェック /26 Corline Biomedicalは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長37.9%収益成長率47.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日11 May 2026今後の成長に関する最新情報Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.すべての更新を表示Recent updates分析記事 • May 11We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Apr 26Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.59m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.お知らせ • Apr 08Corline Biomedical AB, Annual General Meeting, May 12, 2026Corline Biomedical AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: premises of advokatfirman lindahl, vaksalagatan 10, uppsala SwedenRecent Insider Transactions • Feb 20Chief Executive Officer recently bought kr145k worth of stockOn the 17th of February, Henrik Nittmar bought around 10k shares on-market at roughly kr14.54 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Henrik has been a buyer over the last 12 months, purchasing a net total of kr377k worth in shares.Reported Earnings • Feb 19Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.62m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Revenue is less than US$1m (kr8.9m revenue, or US$963k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (kr466.2m market cap, or US$50.5m).Reported Earnings • Nov 19Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Revenue: kr1.61m (down 41% from 3Q 2024). Net loss: kr3.36m (loss widened 12% from 3Q 2024). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Pharmaceuticals industry in Sweden.Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024)Second quarter 2025 results: kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024). Revenue: kr2.63m (down 60% from 2Q 2024). Net loss: kr3.26m (loss narrowed 26% from 2Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.New Risk • Aug 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr315.9m market cap, or US$32.7m).Reported Earnings • May 09First quarter 2025 earnings released: kr0.13 loss per share (vs kr0.078 loss in 1Q 2024)First quarter 2025 results: kr0.13 loss per share (further deteriorated from kr0.078 loss in 1Q 2024). Revenue: kr2.23m (down 60% from 1Q 2024). Net loss: kr3.07m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.お知らせ • Apr 10Corline Biomedical AB, Annual General Meeting, May 15, 2025Corline Biomedical AB, Annual General Meeting, May 15, 2025, at 10:00 W. Europe Standard Time. Location: at the premises of advokatfirman lindahl, vaksalagatan 10 in uppsala, uppsala SwedenReported Earnings • Feb 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: kr1.06 loss per share (further deteriorated from kr0.084 loss in FY 2023). Revenue: kr17.7m (down 50% from FY 2023). Net loss: kr23.2m (loss widened kr21.4m from FY 2023). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Tomas Lifvendahl was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.14 loss per share (vs kr0.008 profit in 3Q 2023)Third quarter 2024 results: kr0.14 loss per share (down from kr0.008 profit in 3Q 2023). Revenue: kr2.76m (down 66% from 3Q 2023). Net loss: kr3.00m (down kr3.18m from profit in 3Q 2023). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (further deteriorated from kr0.11 loss in 2Q 2023). Revenue: kr6.55m (down 24% from 2Q 2023). Net loss: kr4.37m (loss widened 82% from 2Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.分析記事 • Aug 24Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • May 05First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023)First quarter 2024 results: kr0.078 loss per share (down from kr0.047 profit in 1Q 2023). Revenue: kr5.64m (down 45% from 1Q 2023). Net loss: kr1.67m (down 264% from profit in 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • May 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr9.7m free cash flow). Minor Risks Revenue is less than US$5m (kr36m revenue, or US$3.3m). Market cap is less than US$100m (kr226.7m market cap, or US$20.9m).分析記事 • Mar 15We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Feb 16Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022)Full year 2023 results: kr0.084 loss per share (down from kr0.11 profit in FY 2022). Revenue: kr35.9m (up 10% from FY 2022). Net loss: kr1.81m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 31+ 1 more updateCorline Biomedical AB to Report Nine Months, 2024 Results on Nov 07, 2024Corline Biomedical AB announced that they will report nine months, 2024 results on Nov 07, 2024お知らせ • Nov 03Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024Corline Biomedical AB announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022)Second quarter 2023 results: kr0.11 loss per share (down from kr0.041 profit in 2Q 2022). Revenue: kr8.60m (up 20% from 2Q 2022). Net loss: kr2.41m (down 375% from profit in 2Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risks Revenue is less than US$5m (kr38m revenue, or US$3.5m). Market cap is less than US$100m (kr306.2m market cap, or US$28.3m).Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.75, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.Reported Earnings • Apr 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: kr0.11 (up from kr0.34 loss in FY 2021). Revenue: kr32.6m (up 90% from FY 2021). Net income: kr2.33m (up kr9.25m from FY 2021). Profit margin: 7.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Jan 13+ 4 more updatesCorline Biomedical AB to Report First Half, 2023 Results on Aug 25, 2023Corline Biomedical AB announced that they will report first half, 2023 results on Aug 25, 2023Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.091 (up from kr0.097 loss in 3Q 2021). Revenue: kr11.0m (up 275% from 3Q 2021). Net income: kr1.97m (up kr4.04m from 3Q 2021). Profit margin: 18% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.分析記事 • Nov 26We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.041 (up from kr0.10 loss in 2Q 2021). Revenue: kr7.31m (up 117% from 2Q 2021). Net income: kr875.0k (up kr3.03m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 39%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.分析記事 • Jun 22Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.04 loss per share (up from kr0.08 loss in 1Q 2021). Revenue: kr4.53m (up 65% from 1Q 2021). Net loss: kr852.0k (loss narrowed 39% from 1Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 168%, compared to a 95% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.分析記事 • Feb 16We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.097 loss per share (up from kr0.13 loss in 3Q 2020). Revenue: kr2.92m (up 97% from 3Q 2020). Net loss: kr2.08m (loss narrowed 3.4% from 3Q 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4%, compared to a 117% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 27Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr3.37m (down 11% from 2Q 2020). Net loss: kr2.15m (loss narrowed 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.分析記事 • Jun 14Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr2.76m (down 36% from 1Q 2020). Net loss: kr1.41m (loss narrowed 44% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 01Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investorsCorline Biomedical AB (OM:CLBIO) announced that it has issued 3,300,000 shares at issue price of SEK 10.75 per share for gross proceeds of SEK 35,475,000 on March 30, 2021. The transaction included participation from Swedish institutional investors including new investor, M2 Asset Management AB (publ) and returning investor, HealthInvest Partners AB.分析記事 • Feb 28Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Feb 28Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr15.1m (up 27% from FY 2019). Net loss: kr7.29m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 15New 90-day low: kr13.80The company is down 13% from its price of kr15.95 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 13New 90-day low: kr13.85The company is down 17% from its price of kr16.65 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.お知らせ • Dec 19Corline Biomedical AB, Annual General Meeting, May 14, 2021Corline Biomedical AB, Annual General Meeting, May 14, 2021.Is New 90 Day High Low • Dec 01New 90-day low: kr15.10The company is down 8.0% from its price of kr16.35 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.13 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: kr1.49m (down 31% from 3Q 2019). Net loss: kr2.15m (loss widened 11% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.お知らせ • Aug 30Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021Corline Biomedical AB announced that they will report Q4, 2020 results on Jan 26, 2021業績と収益の成長予測OM:CLBIO - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028143N/AN/AN/A112/31/202795N/AN/AN/A112/31/202642N/AN/A1613/31/202611-14-19-18N/A12/31/20259-15-19-18N/A9/30/20259-24-18-17N/A6/30/202510-23-21-19N/A3/31/202514-25-23-17N/A12/31/202417-23-16-9N/A9/30/202424-10-100N/A6/30/202429-6-92N/A3/31/202431-4-37N/A12/31/202336-2-101N/A9/30/202337-1-12-2N/A6/30/2023401-120N/A3/31/2023384-16-5N/A12/31/2022332-15-6N/A9/30/2022311-14-2N/A6/30/202223-3-15-6N/A3/31/202219-6-16-6N/A12/31/202117-7-14-5N/A9/30/202115-6-12-6N/A6/30/202113-6-12-7N/A3/31/202114-6-12-6N/A12/31/202015-7-14-5N/A9/30/202014-9-20-7N/A6/30/202014-9-20-9N/A3/31/202014-9-20-11N/A12/31/201912-10N/A-14N/A9/30/201911-9N/A-17N/A6/30/201911-9N/A-5N/A3/31/201910-8N/A-4N/A12/31/201810-7N/A-4N/A9/30/201817-7N/A-6N/A6/30/201816-6N/A-15N/A3/31/201815-7N/A-16N/A12/31/201716-8N/A-5N/A9/30/20177-8N/A-2N/A6/30/20179-8N/A-2N/A3/31/201710-6N/A1N/A12/31/20169-5N/A-7N/A9/30/20168-6N/A-5N/A6/30/20167-6N/A-4N/A3/31/20165-7N/A-5N/A12/31/20154-6N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CLBIOの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CLBIOの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CLBIOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CLBIOの収益 ( 47.3% ) Swedish市場 ( -1.3% ) よりも速いペースで成長すると予測されています。高い収益成長: CLBIOの収益 ( 47.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CLBIOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 16:38終値2026/08/14 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Corline Biomedical AB 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Gustaf MeyerRedeye
Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.
Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.
Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.
Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.
分析記事 • May 11We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Apr 26Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.59m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 08Corline Biomedical AB, Annual General Meeting, May 12, 2026Corline Biomedical AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: premises of advokatfirman lindahl, vaksalagatan 10, uppsala Sweden
Recent Insider Transactions • Feb 20Chief Executive Officer recently bought kr145k worth of stockOn the 17th of February, Henrik Nittmar bought around 10k shares on-market at roughly kr14.54 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Henrik has been a buyer over the last 12 months, purchasing a net total of kr377k worth in shares.
Reported Earnings • Feb 19Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024)Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.62m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
Price Target Changed • Feb 18Price target decreased by 12% to kr29.00Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year.
New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Revenue is less than US$1m (kr8.9m revenue, or US$963k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (kr466.2m market cap, or US$50.5m).
Reported Earnings • Nov 19Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Revenue: kr1.61m (down 41% from 3Q 2024). Net loss: kr3.36m (loss widened 12% from 3Q 2024). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Pharmaceuticals industry in Sweden.
Price Target Changed • Sep 02Price target increased by 14% to kr21.00Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year.
Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024)Second quarter 2025 results: kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024). Revenue: kr2.63m (down 60% from 2Q 2024). Net loss: kr3.26m (loss narrowed 26% from 2Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.
New Risk • Aug 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr315.9m market cap, or US$32.7m).
Reported Earnings • May 09First quarter 2025 earnings released: kr0.13 loss per share (vs kr0.078 loss in 1Q 2024)First quarter 2025 results: kr0.13 loss per share (further deteriorated from kr0.078 loss in 1Q 2024). Revenue: kr2.23m (down 60% from 1Q 2024). Net loss: kr3.07m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 10Corline Biomedical AB, Annual General Meeting, May 15, 2025Corline Biomedical AB, Annual General Meeting, May 15, 2025, at 10:00 W. Europe Standard Time. Location: at the premises of advokatfirman lindahl, vaksalagatan 10 in uppsala, uppsala Sweden
Reported Earnings • Feb 18Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: kr1.06 loss per share (further deteriorated from kr0.084 loss in FY 2023). Revenue: kr17.7m (down 50% from FY 2023). Net loss: kr23.2m (loss widened kr21.4m from FY 2023). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Tomas Lifvendahl was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 08Third quarter 2024 earnings released: kr0.14 loss per share (vs kr0.008 profit in 3Q 2023)Third quarter 2024 results: kr0.14 loss per share (down from kr0.008 profit in 3Q 2023). Revenue: kr2.76m (down 66% from 3Q 2023). Net loss: kr3.00m (down kr3.18m from profit in 3Q 2023). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (further deteriorated from kr0.11 loss in 2Q 2023). Revenue: kr6.55m (down 24% from 2Q 2023). Net loss: kr4.37m (loss widened 82% from 2Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
分析記事 • Aug 24Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • May 05First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023)First quarter 2024 results: kr0.078 loss per share (down from kr0.047 profit in 1Q 2023). Revenue: kr5.64m (down 45% from 1Q 2023). Net loss: kr1.67m (down 264% from profit in 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • May 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr9.7m free cash flow). Minor Risks Revenue is less than US$5m (kr36m revenue, or US$3.3m). Market cap is less than US$100m (kr226.7m market cap, or US$20.9m).
分析記事 • Mar 15We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Feb 16Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022)Full year 2023 results: kr0.084 loss per share (down from kr0.11 profit in FY 2022). Revenue: kr35.9m (up 10% from FY 2022). Net loss: kr1.81m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 31+ 1 more updateCorline Biomedical AB to Report Nine Months, 2024 Results on Nov 07, 2024Corline Biomedical AB announced that they will report nine months, 2024 results on Nov 07, 2024
お知らせ • Nov 03Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024Corline Biomedical AB announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Aug 28Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022)Second quarter 2023 results: kr0.11 loss per share (down from kr0.041 profit in 2Q 2022). Revenue: kr8.60m (up 20% from 2Q 2022). Net loss: kr2.41m (down 375% from profit in 2Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risks Revenue is less than US$5m (kr38m revenue, or US$3.5m). Market cap is less than US$100m (kr306.2m market cap, or US$28.3m).
Price Target Changed • Jun 30Price target increased by 30% to kr39.00Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year.
Valuation Update With 7 Day Price Move • May 05Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.75, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.
Reported Earnings • Apr 18Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: kr0.11 (up from kr0.34 loss in FY 2021). Revenue: kr32.6m (up 90% from FY 2021). Net income: kr2.33m (up kr9.25m from FY 2021). Profit margin: 7.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Jan 13+ 4 more updatesCorline Biomedical AB to Report First Half, 2023 Results on Aug 25, 2023Corline Biomedical AB announced that they will report first half, 2023 results on Aug 25, 2023
Reported Earnings • Nov 27Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021)Third quarter 2022 results: EPS: kr0.091 (up from kr0.097 loss in 3Q 2021). Revenue: kr11.0m (up 275% from 3Q 2021). Net income: kr1.97m (up kr4.04m from 3Q 2021). Profit margin: 18% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
分析記事 • Nov 26We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Aug 28Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021)Second quarter 2022 results: EPS: kr0.041 (up from kr0.10 loss in 2Q 2021). Revenue: kr7.31m (up 117% from 2Q 2021). Net income: kr875.0k (up kr3.03m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 39%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
分析記事 • Jun 22Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Breakeven Date Change • May 19Forecast breakeven date pushed back to 2024The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule.
Reported Earnings • May 16First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: kr0.04 loss per share (up from kr0.08 loss in 1Q 2021). Revenue: kr4.53m (up 65% from 1Q 2021). Net loss: kr852.0k (loss narrowed 39% from 1Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 168%, compared to a 95% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
分析記事 • Feb 16We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Nov 28Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.097 loss per share (up from kr0.13 loss in 3Q 2020). Revenue: kr2.92m (up 97% from 3Q 2020). Net loss: kr2.08m (loss narrowed 3.4% from 3Q 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4%, compared to a 117% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 27Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr3.37m (down 11% from 2Q 2020). Net loss: kr2.15m (loss narrowed 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
分析記事 • Jun 14Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020)The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr2.76m (down 36% from 1Q 2020). Net loss: kr1.41m (loss narrowed 44% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 01Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investorsCorline Biomedical AB (OM:CLBIO) announced that it has issued 3,300,000 shares at issue price of SEK 10.75 per share for gross proceeds of SEK 35,475,000 on March 30, 2021. The transaction included participation from Swedish institutional investors including new investor, M2 Asset Management AB (publ) and returning investor, HealthInvest Partners AB.
分析記事 • Feb 28Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Feb 28Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr15.1m (up 27% from FY 2019). Net loss: kr7.29m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 15New 90-day low: kr13.80The company is down 13% from its price of kr15.95 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 13New 90-day low: kr13.85The company is down 17% from its price of kr16.65 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
お知らせ • Dec 19Corline Biomedical AB, Annual General Meeting, May 14, 2021Corline Biomedical AB, Annual General Meeting, May 14, 2021.
Is New 90 Day High Low • Dec 01New 90-day low: kr15.10The company is down 8.0% from its price of kr16.35 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.13 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: kr1.49m (down 31% from 3Q 2019). Net loss: kr2.15m (loss widened 11% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
お知らせ • Aug 30Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021Corline Biomedical AB announced that they will report Q4, 2020 results on Jan 26, 2021